Live
FierceBiotechFDA celebrates progress to end animal testing but experts warn there’s still a long way to goFierceBiotechAACR: Former Genentech leader engineers startup with vision for ‘smart’ cancer drugsAgilentAgilent Cancer Research Push Spurs Collaboration Focus And Investor Reassessment - Yahoo FinanceCytiva (Google News)50mm Diameter Filters Cytiva Whatman Cellulose Acetate Membranes:Filters And Filtration Sterile Filtration Membrane - primetimes.id10x Genomics Blog10x Genomics (TXG) Launches Atera: A Breakthrough in Spatial Bio - GuruFocus10x Genomics Blog10x Genomics announces Atera, a new in situ spatial biology platform - TipRanksAgilent11,390 Shares in Agilent Technologies, Inc. $A Acquired by Lecap Asset Management Ltd. - MarketBeatThermo FisherIs Thermo Fisher Scientific (TMO) Fairly Priced After Recent Share Price Rebound? - simplywall.stWatersPrecision Trading with Waters Corporation (WAT) Risk Zones - Stock Traders DailyLonza NewsLonza Group AG stock (CH0013841017): Why biopharma contract manufacturing now matters more for U.S. - AD HOC NEWS10x Genomics Blog10x Genomics Launches Atera Platform for Spatial Biology - Intellectia AILonza NewsLonza Group AG stock (CH0013841017): Is its biopharma contract strength enough for steady U.S. inves - AD HOC NEWS
Endpoints News Feb 28, 2026

Novartis' Rhapsido shows promise in Phase 2 food allergy data

Novartis' Rhapsido shows promise in Phase 2 food allergy data

Original
Body unavailable. Use the original source.